Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial - Cella, D; Motzer, RJ; Suarez, C (Lancet Oncol, 2022)
et al.